The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...
In India, non-alcoholic fatty liver disease (NAFLD) has become a silent epidemic. According to recent data from the Phenome India-CSIR Health Cohort, published in The Lancet Regional Health Southeast ...
A new study suggests that even modest amounts of this carbonated beverage may be associated with higher rates of metabolic fatty liver disease. A new study, published in the Annals of Hepatology, ...
Replacing drinking water entirely with sugar-sweetened or sugar-free cola for eight weeks altered gut microbiota composition ...
Altimmune, Inc. (ALT) announced on Monday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation (BTD) for its drug pemvidutide. The drug, a 1:1 glucagon/GLP-1 dual ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results